In response to the possible quality risks of some centrally purchased drugs, the National Medical Insurance Administration took the lead in the investigation

On January 20, the National Medical Insurance Bureau said today (20th) that during the recent "two sessions" in Shanghai, some members of the Chinese People's Political Consultative Conference and medical experts reported that some collectively purchased drugs may have quality risks and other issues, and the National Medical Insurance Bureau attaches great importance to them. In order to effectively accept democratic supervision, widely listen to the voices of the clinical front line, give full play to the professional role of doctors, obtain first-hand direct evidence of the effectiveness of clinical use of pooled drugs, and further safeguard the order of pooled drugs and safeguard the health rights and interests of the people, it was decided that on January 21, the responsible comrades of the National Medical Insurance Bureau led a team to join the health, industrial informatization, and drug regulatory departments to go to Shanghai to listen to the opinions and suggestions of relevant members and experts on the policy of pooled drug procurement and the quality assurance of selected products, and focus on collecting clues on quality and efficacy problems supported by clinical data and statistically diverse.